Beyond AirXAIR
XAIR
About: Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
Employees: 107
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
367% more call options, than puts
Call options by funds: $14K | Put options by funds: $3K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
4% less funds holding
Funds holding: 45 [Q4 2024] → 43 (-2) [Q1 2025]
6.78% less ownership
Funds ownership: 28.56% [Q4 2024] → 21.78% (-6.78%) [Q1 2025]
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
29% less capital invested
Capital invested by funds: $7.39M [Q4 2024] → $5.24M (-$2.15M) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 12
Research analyst outlook
We haven’t received any recent analyst ratings for XAIR.
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
Beyond Air Schedules Fiscal Year End 2025 Financial Results Conference Call and Webcast
GARDEN CITY, N.Y., May 20, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2025 on Tuesday, June 17, 2025. The Company's management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.
Neutral
GlobeNewsWire
1 month ago
NeuroNOS Granted FDA Orphan Drug Designation for Phelan-McDermid Syndrome, a Neurodevelopmental Disorder Linked to Autism
The FDA d esignation m arks a s ignificant m ilestone in the d evelopment of a n ovel t reatment for a r are n eurodevelopmental d isorder
Neutral
GlobeNewsWire
1 month ago
NeuroNOS Appoints Nobel Prize Laureate, Professor Dan Shechtman, to Scientific Advisory Board
Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease Professor Shechtman joins fellow Nobel Prize laureate Professor Roger Kornberg to advance the development of treatments for Autism Spectrum Disorder and Alzheimer's Disease
Neutral
GlobeNewsWire
2 months ago
Beyond Air Publishes Article in Annals of the American Thoracic Society Journal Highlighting NTM-PD Patients' Ability to Safely Self-Administer High-Dose Intermittent iNO Treatments Using the LungFit™ GO at Home
GARDEN CITY, N.Y., April 09, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the publication of its scientific article, “A Pilot Study to Assess the Effect of Intermittent Inhaled Nitric Oxide as Treatment of Nontuberculous Mycobacteria Lung Infection” in Annals of the American Thoracic Society, an online peer-reviewed journal. The article is available online at (click here).
Neutral
GlobeNewsWire
2 months ago
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site
As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology
Neutral
GlobeNewsWire
2 months ago
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy
First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, including Alzheimer's disease and brain cancers, and a subsidiary of Beyond Air (NASDAQ: XAIR), has secured an initial $2 million in equity financing from private investors as part of a larger funding round. This investment will accelerate the preclinical development of NeuroNOS's small-molecule drug, designed as an injectable or oral treatment for children with autism.
Neutral
GlobeNewsWire
3 months ago
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH
Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, announced the expansion of its global distribution channels for LungFit PH with several new distribution agreements that will cover four countries, including France, Romania, Turkey and Morocco.
Neutral
GlobeNewsWire
3 months ago
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Conference being held April 8-9, 2025 in Las Vegas, NV.
Neutral
Seeking Alpha
4 months ago
Beyond Air, Inc. (XAIR) Q3 2025 Earnings Call Transcript
Beyond Air, Inc. (NASDAQ:XAIR ) Q3 2025 Results Conference Call February 10, 2025 4:30 PM ET Company Participants Corey Davis - Investor Relations, LifeSci Advisors Steve Lisi - Chairman and Chief Executive Officer Doug Larson - Chief Financial Officer Conference Call Participants Jason Wittes - Roth Partners Sam Eiber - BTIG Jason Bednar - Piper Sandler Justin Walsh - JonesTrading Yale Jen - Laidlaw & Company Operator Good afternoon, and welcome everyone to the Beyond Air Financial Results Call for the Fiscal Quarter Ended December 31, 2024. At this time, all participants are in a listen-only mode.
Negative
Zacks Investment Research
4 months ago
Beyond Air, Inc. (XAIR) Reports Q3 Loss, Tops Revenue Estimates
Beyond Air, Inc. (XAIR) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.50 per share a year ago.
Charts implemented using Lightweight Charts™